Frontiers Clinical and Translational Science Institute at the University of Kansas

堪萨斯大学前沿临床与转化科学研究所

• 批准号: 10702087
• 负责人: Mario Castro
• 金额: $ 11.23万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-07 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10702087
• 关键词: Acceleration; Address; Administrative Supplement; COVID-19; Career Mobility; Cities; Clinical Informatics; Clinical Management; Clinical Research; Clinical Sciences; Collaborations; Communities; Creativeness; Data; Data Set; Decision Making; Discipline; Diverse Workforce; Ensure; Exclusion; Fostering; Genomic medicine; Genomics; Goals; Grant; Health; Health Priorities; Healthcare Systems; Individual; Informatics; Institution; Intervention; Kansas; Knowledge; Leadership; Longevity; Maps; Methods; Midwestern United States; Missouri; National Center for Advancing Translational Sciences; Patients; Population; Process; Research; Research Design; Research Methodology; Research Personnel; Rural; Rural Community; Science; Specialist; Structure; System; TNFSF15 gene; Training; Translating; Translational Research; Underrepresented Populations; Universities; Vision; career development; catalyst; community organizations; design; experience; frontier; health care quality; health equity; human subject; improved; innovation; nano; novel; patient advocacy group; point of care; programs; symposium; tool

OVERALL UL1 PROJECT SUMMARY/ABSTRACT The Frontiers Clinical and Translational Science Institute at the University of Kansas (Frontiers) has been a catalyst for clinical and translational research (CTR) across the Kansas City region. The vision of Frontiers 3.0 is to transform the way we do CTR and ensure that research is rapidly translated to the point of care in a way that improves health for underserved and excluded populations, especially those in rural communities. To do so, we have expanded Frontiers 3.0 partners to include multiple academic institutions, healthcare systems, and community organizations and patient advocacy groups across Kansas and western Missouri. Our new shared leadership structure balances power across institutions. The overall aims of Frontiers are: Aim 1. Train a diverse workforce that leverages multiple disciplines, frameworks and approaches to stimulate creative, responsive and impactful T1-T4 clinical and translational research. Frontiers cores and its KL2 and TL1 programs provide high quality training, assistance in research design and implementation, guidance in applying for grants, and support for career advancement for all levels translational research trainees. In Frontiers 3.0 we emphasize identifying and supporting investigators from underrepresented groups and those with a research focus on underserved and excluded populations. Aim 2. Collaborate and engage with underserved and excluded communities to ensure that clinical and translational research is responsive to their priorities and achieves greater health equity. Frontiers 3.0 hosts Design Studios, Fieldwork Nano-experiences, Story-telling sessions, Community Co- Investigator Human Subjects Training and Conferences to support collaborations between researchers and patients, communities, and stakeholders. New advisory groups of community partners and community- engaged researchers provide guidance at all levels of Frontiers decisionmaking. We expand our novel efforts to understand and address COVID-19 across the lifespan and among underserved and excluded groups. Aim 3. Drive innovative, quality, and efficient clinical and translational research across the lifespan that harnesses novel informatics, genomics, team science and implementation methods to enhance delivery of high-quality healthcare in the region. Frontiers reduces barriers to entering CTR by providing unparalleled comprehensive support that minimizes regulatory burden and expedites research. New cores provide entre to tools and data for pursuing genomic medicine and help investigators access and analyze rich datasets available via clinical informatics. New leadership in Team Science will map investigator networks, identify gaps, and introduce individual and team- level interventions to help investigators build and maintain effective teams. Frontiers will accelerate CTR in the Midwest and build a workforce that attends to health priorities for the rural, underserved, and excluded. Our discoveries and new tools will contribute to knowledge for the nation.

UL1 项目总体总结/摘要 堪萨斯大学前沿临床与转化科学研究所（Frontiers） 堪萨斯城地区临床和转化研究 (CTR) 的催化剂。 Frontiers 3.0的愿景 是改变我们进行 CTR 的方式，并确保研究以某种方式快速转化为护理点 改善服务不足和被排斥人群的健康，特别是农村社区的人群。要做的事 因此，我们扩大了 Frontiers 3.0 合作伙伴，包括多个学术机构、医疗保健系统和 堪萨斯州和密苏里州西部的社区组织和患者倡导团体。我们的新共享 领导结构平衡机构之间的权力。 Frontiers 的总体目标是： 目标 1. 培训一支多元化的劳动力队伍，利用多种学科、框架和方法来激励 创造性、反应灵敏和有影响力的 T1-T4 临床和转化研究。 Frontiers 核心及其 KL2 和 TL1 项目提供高质量的培训、研究设计和支持 实施、申请补助金的指导以及对各级职业发展的支持 研究实习生。在 Frontiers 3.0 中，我们强调识别和支持来自以下领域的研究人员： 代表性不足的群体以及研究重点是服务不足和被排斥群体的群体。 目标 2. 与服务不足和被排斥的社区合作并参与，以确保临床和 转化研究响应他们的优先事项并实现更大的健康公平。 Frontiers 3.0 举办设计工作室、实地考察纳米体验、讲故事会议、社区合作 研究者人类受试者培训和会议，以支持研究人员和研究人员之间的合作 患者、社区和利益相关者。由社区合作伙伴和社区组成的新咨询小组 参与的研究人员为各个层面的前沿决策提供指导。我们扩大我们的创新努力 了解和应对整个生命周期中以及服务不足和被排斥群体中的 COVID-19。 目标 3. 在整个生命周期内推动创新、优质、高效的临床和转化研究 利用新颖的信息学、基因组学、团队科学和实施方法来增强交付 该地区的高质量医疗保健。 Frontiers 通过提供无与伦比的全面支持，最大限度地减少进入 CTR 的障碍 监管负担并加快研究速度。新核心为研究基因组学提供了工具和数据入口 医学并帮助研究人员访问和分析通过临床信息学提供的丰富数据集。新的 团队科学的领导力将绘制研究者网络、找出差距并引入个人和团队- 级干预措施，帮助调查人员建立和维持有效的团队。 Frontiers 将加快中西部地区的 CTR，并建立一支致力于农村地区卫生优先事项的劳动力队伍， 服务不足，并被排除在外。我们的发现和新工具将为国家贡献知识。

项目成果

Estrogen Signaling Dictates Musculoskeletal Stem Cell Behavior: Sex Differences in Tissue Repair.

• DOI: 10.1089/ten.teb.2021.0094
• 发表时间: 2022-08
• 期刊: TISSUE ENGINEERING PART B-REVIEWS
• 影响因子: 6.4
• 作者: Knewtson, Kelsey E.;Ohl, Nathan R.;Robinson, Jennifer L.
• 通讯作者: Robinson, Jennifer L.

Effects of genotype and food on naltrexone exposure in adolescents.

• DOI: 10.1111/cts.13399
• 发表时间: 2022-11
• 期刊: Clinical and translational science

Measuring Clinical Treatment Response in Myasthenia Gravis.

• DOI: 10.1016/j.ncl.2018.01.006
• 发表时间: 2018-05
• 期刊: Neurologic clinics
• 影响因子: 2.4
• 作者: Barnett C;Herbelin L;Dimachkie MM;Barohn RJ
• 通讯作者: Barohn RJ

Association Between Unmet Essential Social Needs and Influenza Vaccination in US Adults.

• DOI: 10.1007/s11606-021-06902-6
• 发表时间: 2022-01
• 期刊: Journal of general internal medicine
• 影响因子: 5.7
• 作者: Parente DJ;Murray MJ;Woodward J
• 通讯作者: Woodward J

Impact of the Early Phase of the COVID-19 Pandemic on US Healthcare Workers: Results from the HERO Registry.

• DOI: 10.1007/s11606-020-06529-z
• 发表时间: 2021-05
• 期刊: Journal of general internal medicine
• 影响因子: 5.7
• 作者: Forrest CB;Xu H;Thomas LE;Webb LE;Cohen LW;Carey TS;Chuang CH;Daraiseh NM;Kaushal R;McClay JC;Modave F;Nauman E;Todd JV;Wallia A;Bruno C;Hernandez AF;O'Brien EC;HERO Registry Research Group
• 通讯作者: HERO Registry Research Group